Carol Stuckley
Direktor/Vorstandsmitglied bei CENTESSA PHARMACEUTICALS PLC
Vermögen: - $ am 30.04.2024
Aktive Positionen von Carol Stuckley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CENTESSA PHARMACEUTICALS PLC | Direktor/Vorstandsmitglied | 17.05.2021 | - |
Independent Dir/Board Member | 17.05.2021 | - | |
TRANSGENE | Direktor/Vorstandsmitglied | 05.05.2023 | - |
Independent Dir/Board Member | 05.05.2023 | - |
Karriereverlauf von Carol Stuckley
Ehemalige bekannte Positionen von Carol Stuckley
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
EPIZYME, INC. | Direktor/Vorstandsmitglied | 16.11.2021 | 12.08.2022 |
Independent Dir/Board Member | 16.11.2021 | 12.08.2022 | |
IPSEN | Direktor/Vorstandsmitglied | 07.06.2017 | 01.08.2021 |
Independent Dir/Board Member | 07.06.2017 | 01.08.2021 | |
Healthcare Payment Specialists LLC
Healthcare Payment Specialists LLC Miscellaneous Commercial ServicesCommercial Services Healthcare Payment Specialists LLC provides payment and reimbursement solutions. The firm’s solutions include Stingary SAAS, Medicare bad debt, Medicare disproportionate share, Shadow billing compliance, Transfer DRG, Volume decrease adjustment and Complex drug review. It also offers consulting services. The company was founded in 2002 by Peter Jarvis and is headquartered in Fort Worth, TX. | Finanzdirektor/CFO | 01.06.2015 | 01.07.2019 |
Galderma Laboratories LP
Galderma Laboratories LP Pharmaceuticals: MajorHealth Technology Galderma Laboratories LP develops and markets dermatology and prescription products. It also offers treatments for skin conditions such as acne, rosacea, atopic dermatitis, soriasis, melasma and sunspots. Galderma Laboratories was founded in 1961 and is headquartered in Fort Worth, TX. | Finanzdirektor/CFO | 01.01.2010 | 01.01.2013 |
Financial Executives International of Fort Worth Chapter | Direktor/Vorstandsmitglied | - | - |
Präsident | - | - | |
PFIZER, INC. | Finanzdirektor/CFO | - | - |
Ausbildung von Carol Stuckley
Fox School of Business | Graduate Degree |
University of Delaware | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Frankreich | 3 |
Vereinigtes Königreich | 2 |
Operativ
Director/Board Member | 5 |
Independent Dir/Board Member | 4 |
Director of Finance/CFO | 3 |
Sektoral
Health Technology | 7 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
IPSEN | Health Technology |
PFIZER, INC. | Health Technology |
CENTESSA PHARMACEUTICALS PLC | Health Technology |
TRANSGENE | Health Technology |
Private Unternehmen | 4 |
---|---|
Healthcare Payment Specialists LLC
Healthcare Payment Specialists LLC Miscellaneous Commercial ServicesCommercial Services Healthcare Payment Specialists LLC provides payment and reimbursement solutions. The firm’s solutions include Stingary SAAS, Medicare bad debt, Medicare disproportionate share, Shadow billing compliance, Transfer DRG, Volume decrease adjustment and Complex drug review. It also offers consulting services. The company was founded in 2002 by Peter Jarvis and is headquartered in Fort Worth, TX. | Commercial Services |
Galderma Laboratories LP
Galderma Laboratories LP Pharmaceuticals: MajorHealth Technology Galderma Laboratories LP develops and markets dermatology and prescription products. It also offers treatments for skin conditions such as acne, rosacea, atopic dermatitis, soriasis, melasma and sunspots. Galderma Laboratories was founded in 1961 and is headquartered in Fort Worth, TX. | Health Technology |
Financial Executives International of Fort Worth Chapter | |
Epizyme, Inc.
Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Carol Stuckley
- Erfahrung